- REGENXBIO (NASDAQ:RGNX) and Dimension Therapeutics (NASDAQ:DMTX) announces that they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction for an implied value of ~$3.41 per share. The boards of directors of both companies have unanimously approved the transaction.
- Upon completion of the acquisition, REGENXBIO will add two lead product candidates to its pipeline:
- DTX301 for the treatment of ornithine transcarbamylase deficiency. DTX301 is being evaluated under an active investigational new drug (IND) application for a Phase I/II clinical trial; and
- DTX401 for the treatment of glycogen storage disease type Ia (GSDIa).
- Both DTX301 and DTX401 have been granted Orphan Drug Designation in the US and Europe.
- REGENXBIO will also acquire DTX201 for the treatment of hemophilia A. An IND application for both DTX401 and DTX201 is anticipated to be filed in early 2018.
- Acquisition will enhance REGENXBIO’s pipeline of gene therapy product candidates, with the potential to achieve multiple milestones through the end of 2018.
- REGENXBIO will acquire preclinical product candidates, manufacturing technology and other intellectual property developed by Dimension.
- Dimension shareholders will receive 0.1573 shares of REGENXBIO in exchange for each of their shares in Dimension and are expected to own ~10.9% percent of the combined entity. The transaction should close by year-end.
- Shares of Dimension Therapeutics (DMTX) are up 163% premarket.
- Now read: Lexicon Pharmaceuticals: Stock Out Of Favor But Fundamentals Improving
Original article